본문 바로가기
KERD
논문KCI 등재

파킨슨병의 약물 치료

Pharmacological Treatment in Parkinson’s Disease

이재정
대한신경과학회 (Korean Neurological Association)|2019.11|대한신경과학회지 (Journal of the Korean Neurological Association)|제37권 제4호|pp. 335-344|DOI https://doi.org/10.17340/jkna.2019.4.1

0

조회

0

다운로드

10

인용

0

참고문헌

키워드

Drug therapyParkinson disease
주제분류신경과학

초록

practically not available yet, symptomatic managements using anti-Parkinson medications have shown to be quite effective to improve patients’ quality of life. The discovery of dopaminergic deficits in Parkinson’s disease in 1960s have brought about the human clinical trials of levodopa, which opened an “Era of Dopamine” in treatment history of the Parkinson’s disease. Levodopa still remains gold standard. Dopamine agonists have proved their efficacies and delayed the development of long-term complications of levodopa use. Inhibitors of respective enzyme monoamine oxidase-B and catechol-O-methyltransferase, anticholinergics, and amantadine strengthen the therapeutic effects via either monotherapy or adjunctive way. Strategy of continuous dopaminergic stimulation and disease modification are weighing in current advances. This article is providing evidence-based review of pharmacological treatment of Parkinson’s disease from early to advanced stages as well as management its unavoidable adverse reactions.

Abstract

practically not available yet, symptomatic managements using anti-Parkinson medications have shown to be quite effective to improve patients’ quality of life. The discovery of dopaminergic deficits in Parkinson’s disease in 1960s have brought about the human clinical trials of levodopa, which opened an “Era of Dopamine” in treatment history of the Parkinson’s disease. Levodopa still remains gold standard. Dopamine agonists have proved their efficacies and delayed the development of long-term complications of levodopa use. Inhibitors of respective enzyme monoamine oxidase-B and catechol-O-methyltransferase, anticholinergics, and amantadine strengthen the therapeutic effects via either monotherapy or adjunctive way. Strategy of continuous dopaminergic stimulation and disease modification are weighing in current advances. This article is providing evidence-based review of pharmacological treatment of Parkinson’s disease from early to advanced stages as well as management its unavoidable adverse reactions.

참고문헌 (57)

  1. Rascol O, "Milestones in Parkinson's disease therapeutics", Mov Disord, 26, pp.1072~1082 (2011)
  2. LeWitt PA, "Is levodopa toxic? Insights from a brain bank", Neurology, 77, pp.1414~1415 (2011)
  3. Chan PL, "Levodopa slows progression of Parkinson's disease : external validation by clinical trial simulation", Pharm Res, 24, pp.791~802 (2007)
  4. Olanow CW, "Levodopa in the treatment of Parkinson's disease : current controversies", Mov Disord, 19, pp.997~1005 (2004)
  5. Katzenschlager R, "Treatment of Parkinson's disease: levodopa as the first choice", J Neurol, 249(Suppl 2), pp.II19~II24 (2002)
  6. Grosset D, "A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis", J Neurol Neurosurg Psychiatry, 78, pp.465~469 (2007)
  7. Schapira AH, "Timing of treatment initiation in Parkinson's disease : a need for reappraisal", Ann Neurol, 59, pp.559~562 (2006)
  8. Verschuur CVM, "Randomized delayed-start trial of levodopa in Parkinson's disease", N Engl J Med, 380, pp.315~324 (2019)
  9. Palhagen S, "Selegiline slows the progression of the symptoms of Parkinson disease", Neurology, 66, pp.1200~1206 (2006)
  10. "A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study", Arch Neurol, 59, pp.1937~1943 (2002)
  11. Olanow CW, "A double-blind, delayed-start trial of rasagiline in Parkinson's disease", N Engl J Med, 361, pp.1268~1278 (2009)
  12. Hauser RA, "Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease", Mov Disord, 29, pp.1028~1034 (2014)
  13. Heinonen EH, "Safety of selegiline(deprenyl)in the treatment of Parkinson's disease", Drug Saf, 19, pp.11~22 (1998)
  14. Horstink M, "Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease", Eur J Neurol, 13, pp.1170~1185 (2006)
  15. Parkes JD, "Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease", J Neurol Neurosurg Psychiatry, 37, pp.422~426 (1974)
  16. Martin WE, "A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease", Neurology, 24, pp.912~919 (1974)
  17. Katzenschlager R, "Anticholinergics for symptomatic management of Parkinson's disease", Cochrane Database Syst Rev, (2), pp.CD003735~ (2003)
  18. Lang AE, "Management of Parkinson's disease: an evidence-based review", Mov Disord, 17(Suppl 4), pp.S1~S166 (2002)
  19. Savery F, "Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease", Dis Nerv Syst, 38, pp.605~608 (1977)
  20. Connolly BS, "Pharmacological treatment of Parkinson disease : a review", JAMA, 311, pp.1670~1683 (2014)
  21. Ferreira JJ, "Summary of the recommendations of the EFNS", MDS-ES review on therapeutic management of Parkinson's disease, 2013, pp.20, 5~15
  22. LeWitt PA, "Levodopa therapy for Parkinson disease: a look backward and forward", Neurology, 86(14 Suppl 1), pp.S3~S12 (2016)
  23. Fox SH, "The movement disorder society evidence-based medicine review update:treatments for the motor symptoms of Parkinson's disease", Mov Disord, 26(Suppl 3), pp.S2~S41 (2011)
  24. Rascol O, "A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa", N Engl J Med, 342, pp.1484~1491 (2000)
  25. Holloway RG, "Pramipexole vs levodopa as initial treatment for Parkinson disease : a 4-year randomized controlled trial", Arch Neurol, 61, pp.1044~1053 (2004)
  26. Antonini A, "A reassessment of risks and benefits of dopamine agonists in Parkinson's disease", Lancet Neurol, 8, pp.929~937 (2009)
  27. Jankovic J, "Therapies in Parkinson's disease", Curr Opin Neurol, 25, pp.433~447 (2012)
  28. "Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group", JAMA, 278, pp.125~130 (1997)
  29. Hauser RA, "Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease", Mov Disord, 25, pp.2542~2549 (2010)
  30. Adler CH, "Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group", Neurology, 49, pp.393~399 (1997)
  31. Stocchi F, "Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease : a randomized, double-blind, non-inferiority crossover study", Curr Med Res Opin, 24, pp.2883~2895 (2008)
  32. Parkinson Study Group, "A controlled trial of rotigotine monotherapy in early Parkinson's disease", Arch Neurol, 60, pp.1721~1728 (2003)
  33. Etminan M, "Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease : a meta-analysis of randomised controlled trials", Drug Saf, 24, pp.863~868 (2001)
  34. Pahwa R, "Treatment of early Parkinson's disease", Curr Opin Neurol, 27, pp.442~449 (2014)
  35. Schrag A, "Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study", Brain, 123(Pt 11), pp.2297~2305 (2000)
  36. Ahlskog JE, "Controlled-release sinemet(CR-4) : a double-blind crossover study in patients with fluctuating Parkinson's disease", Mayo Clin Proc, 63, pp.876~886 (1988)
  37. Jankovic J, "Comparison of sinemet CR4and standard sinemet : double blind and long-term open trial in parkinsonian patients with fluctuations", Mov Disord, 4, pp.303~309 (1989)
  38. Pahwa R, "Randomized trial of IPX066, carbidopa", levodopa extended release, in early Parkinson's disease, 2014, pp.20, 142~148
  39. Olanow CW, "Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease : a randomised, controlled, double-blind, double-dummy study", Lancet Neurol, 13, pp.141~149 (2014)
  40. Lotia M, "New and emerging medical therapies in Parkinson's disease", Expert Opin Pharmacother, 17, pp.895~909 (2016)
  41. LeWitt PA, "A randomized trial of inhaled levodopa(CVT-301)for motor fluctuations in Parkinson's disease", Mov Disord, 31, pp.1356~1365 (2016)
  42. Schapira AH, "Extended-release pramipexole in advanced Parkinson disease : a randomized controlled trial", Neurology, 77, pp.767~774 (2011)
  43. Mizuno Y, "Efficacy and safety of extended-versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease : a double-blind, randomized trial", Clin Neuropharmacol, 35, pp.174~181 (2012)
  44. Zhang Z, "The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease : a multicenter, double-blind, randomized, placebo-controlled study", Parkinsonism Relat Disord, 19, pp.1022~1026 (2013)
  45. Mizuno Y, "Rotigotine vs ropinirole in advanced stage Parkinson's disease : a double-blind study", Parkinsonism Relat Disord, 20, pp.1388~1393 (2014)
  46. Fox SH, "International Parkinson and movement disorder society evidence-based medicine review : update on treatments for the motor symptoms of Parkinson's disease", Mov Disord, 33, pp.1248~1266 (2018)
  47. Goetz CG, "Evidence-based medical review update : pharmacological and surgical treatments of Parkinson's disease : 2001 to 2004", Mov Disord, 20, pp.523~539 (2005)
  48. Borgohain R, "Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations", Mov Disord, 29, pp.229~237 (2014)
  49. Thomas A, "Duration of amantadine benefit on dyskinesia of severe Parkinson's disease", J Neurol Neurosurg Psychiatry, 75, pp.141~143 (2004)
  50. Postuma R, "Physician guide non-motor symptoms of Parkinson’s disease", McGill University Health Centre, 7~9 (2012)
  51. Chen JJ, "Treatment of psychotic symptoms in patients with Parkinson disease", Ment Health Clin, 7, pp.262~270 (2018)
  52. Cummings J, "Pimavanserin for patients with Parkinson's disease psychosis : a randomised, placebo-controlled phase 3 trial", Lancet, 383, pp.533~540 (2014)
  53. Molde H, "Impulse-control disorders in Parkinson's disease : a meta-analysis and review of case-control studies", Front Neurol, 9, pp.330~ (2018)
  54. Velseboer DC, "Prevalence of orthostatic hypotension in Parkinson's disease : a systematic review and meta-analysis", Parkinsonism Relat Disord, 17, pp.724~729 (2011)
  55. Horstink M, "Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease", Eur J Neurol, 13, pp.1186~1202 (2006)
  56. Ondo WG, "Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial", J Neurol Neurosurg Psychiatry, 76, pp.1636~1639 (2005)
  57. Sarkar S, "Neuroprotective and therapeutic strategies against Parkinson's disease : recent perspectives", Int J Mol Sci, 17, pp.904~ (2016)

관련 논문AI추천

파킨슨병의 생물표지자: 임상 및 생화학 생물표지자김영은, 마효일, 이주영대한신경과학회 · 대한신경과학회지2021 · 제39권 제4호파킨슨병 환자의 초기 치료로서 레보도파와 도파민 작용제가 인지기능에 미치는 효과권오대, 박재한, 이동국, 최소영대한신경과학회 · 대한신경과학회지2008 · 제26권 제4호파킨슨병 치매의 진단과 치료에 대한 최신 지견박미영영남대학교 의과대학 · Journal of Yeungnam Medical Science2007 · 제24권 제2호Seniors with Parkinson’s Disease: Initial Medical TreatmentJ. Eric Ahlskog대한신경과학회 · Journal of Clinical Neurology2010 · 제6권 제4호레보도파 요법 중인 파킨슨병 환자의 인지장애 위험 인자 연구김경숙, 이경은, 이명구한국임상약학회 · 한국임상약학회지2018 · 제28권 제4호치매의 약물치료백남종, 한수정대한뇌신경재활학회 · 뇌신경재활2015 · 제8권 제1호

이 간행물의 다른 논문 (27건)

뇌사 판정 과정에서 관찰되는 반사 혹은 자발 움직임이정림, 김영수, 김도형, 김민화, 양태원, 김수경, 김주현, 권오영, 조원현pp. 345-351수면클리닉에 방문하는 한국인 환자들의 수면무호흡증에 대한 위험요인김소현, 조용원, 도소영, 김근태pp. 352-360가족성 고콜레스테롤혈증을 동반한 급성 뇌경색 환자의 특징김정민, 박광열, 박소현, 이상학, 김지아pp. 361-367카다실 환자에서 발프로산에 호전된 얼굴변형시증과 시야장애조재욱, 정선혜, 신진홍, 정나연, 황보진pp. 368-371급성 뇌졸중의 증상을 보인 Cefepime뇌병증최병철, 황정수, 이상화, 김영일, 황수범pp. 372-375
원문 보기